USA - NASDAQ:SMLR - US81684M1045 - Common Stock
The current stock price of SMLR is 23 USD. In the past month the price decreased by -6.77%. In the past year, price decreased by -48.29%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.9 | 224.97B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.68 | 202.72B | ||
| BSX | BOSTON SCIENTIFIC CORP | 35.59 | 155.55B | ||
| SYK | STRYKER CORP | 28.35 | 142.76B | ||
| IDXX | IDEXX LABORATORIES INC | 55.63 | 56.12B | ||
| BDX | BECTON DICKINSON AND CO | 13.39 | 55.33B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.51 | 50.56B | ||
| RMD | RESMED INC | 25.47 | 36.79B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.12 | 33.77B | ||
| DXCM | DEXCOM INC | 32.11 | 23.42B | ||
| PODD | INSULET CORP | 72.79 | 23.42B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.2 | 17.94B |
Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. The company is headquartered in Campbell, California and currently employs 79 full-time employees. The company went IPO on 2014-02-27. The firm's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The firm delivers QuantaFlo directly to its customers. The firm also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
SEMLER SCIENTIFIC INC
51 E Campbell Ave, Suite 107-D
Campbell CALIFORNIA 97210 US
CEO: Douglas Murphy-Chutorian
Employees: 79
Phone: 18777744211
Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. The company is headquartered in Campbell, California and currently employs 79 full-time employees. The company went IPO on 2014-02-27. The firm's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The firm delivers QuantaFlo directly to its customers. The firm also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
The current stock price of SMLR is 23 USD. The price decreased by -10.61% in the last trading session.
SMLR does not pay a dividend.
SMLR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
SMLR stock is listed on the Nasdaq exchange.
You can find the ownership structure of SEMLER SCIENTIFIC INC (SMLR) on the Ownership tab.
The outstanding short interest for SEMLER SCIENTIFIC INC (SMLR) is 29.27% of its float.
ChartMill assigns a fundamental rating of 5 / 10 to SMLR. While SMLR belongs to the best of the industry regarding profitability, there are concerns on its financial health.
Over the last trailing twelve months SMLR reported a non-GAAP Earnings per Share(EPS) of 8.41. The EPS increased by 201.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 86.2% | ||
| ROA | 7.09% | ||
| ROE | 9.66% | ||
| Debt/Equity | 0.25 |
9 analysts have analysed SMLR and the average price target is 76.84 USD. This implies a price increase of 234.09% is expected in the next year compared to the current price of 23.
For the next year, analysts expect an EPS growth of -95.59% and a revenue growth -43.54% for SMLR